|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1999-5-13
|
|
pubmed:abstractText |
Monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA) have been recognized as targeting agents for medullary thyroid carcinoma (MTC). This Phase I/II study was initiated to determine the safety, maximum tolerated dose (MTD), and therapeutic potential of (131)I-MN-14 F(ab)2 anti-CEA MAb for patients with metastatic MTC.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Anti-Idiotypic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Calcitonin,
http://linkedlifedata.com/resource/pubmed/chemical/Carcinoembryonic Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoconjugates,
http://linkedlifedata.com/resource/pubmed/chemical/Iodine Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/labetuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1828-42
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10223579-Adult,
pubmed-meshheading:10223579-Aged,
pubmed-meshheading:10223579-Aged, 80 and over,
pubmed-meshheading:10223579-Animals,
pubmed-meshheading:10223579-Antibodies, Anti-Idiotypic,
pubmed-meshheading:10223579-Antibodies, Monoclonal,
pubmed-meshheading:10223579-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:10223579-Antigens, Neoplasm,
pubmed-meshheading:10223579-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10223579-Calcitonin,
pubmed-meshheading:10223579-Carcinoembryonic Antigen,
pubmed-meshheading:10223579-Carcinoma, Medullary,
pubmed-meshheading:10223579-Combined Modality Therapy,
pubmed-meshheading:10223579-Female,
pubmed-meshheading:10223579-Humans,
pubmed-meshheading:10223579-Immunoconjugates,
pubmed-meshheading:10223579-Iodine Radioisotopes,
pubmed-meshheading:10223579-Male,
pubmed-meshheading:10223579-Metabolic Clearance Rate,
pubmed-meshheading:10223579-Mice,
pubmed-meshheading:10223579-Middle Aged,
pubmed-meshheading:10223579-Neck Dissection,
pubmed-meshheading:10223579-Neoplasm Proteins,
pubmed-meshheading:10223579-Radioimmunotherapy,
pubmed-meshheading:10223579-Radiotherapy Dosage,
pubmed-meshheading:10223579-Thyroid Neoplasms,
pubmed-meshheading:10223579-Thyroidectomy,
pubmed-meshheading:10223579-Tissue Distribution,
pubmed-meshheading:10223579-Treatment Outcome
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
|
|
pubmed:affiliation |
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
